Andrey S. Belevskiy

1 Ostrovityanova Str, Bldg. 6
Moscow, MOW 117513, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Cross-Disease Breathomics by PTR-TOF-MS: Multiclass Machine Learning and Network Remodeling Across Asthma, COPD, Cystic Fibrosis, and Lymphangioleiomyomatosis.

Cross-Disease Breathomics by PTR-TOF-MS: Multiclass Machine Learning and Network Remodeling Across Asthma, COPD, Cystic Fibrosis, and Lymphangioleiomyomatosis.

Journal: International journal of molecular sciences

Published: February 23, 2026

Diagnostic Value of Serum VEGF-D in Lymphangioleiomyomatosis: Results of the First Prospective Study in the Russian Federation.

Diagnostic Value of Serum VEGF-D in Lymphangioleiomyomatosis: Results of the First Prospective Study in the Russian Federation.

Journal: Diagnostics (Basel, Switzerland)

Published: November 26, 2025

Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry.

Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry.

Journal: International journal of molecular sciences

Published: March 15, 2025

Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach.

Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach.

Journal: The journal of allergy and clinical immunology. In practice

Published: October 31, 2024

Clinical and morphological features of lung injury long-term after SARS-CoV-2 recovery

Clinical and morphological features of lung injury long-term after SARS-CoV-2 recovery

Journal: Terapevticheskii arkhiv

Published: April 04, 2024

New clinical guidelines for COPD - a paradigm shift: A review

New clinical guidelines for COPD - a paradigm shift: A review

Journal: Terapevticheskii arkhiv

Published: April 04, 2024

Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.

Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.

Journal: Allergy

Published: October 12, 2022

Data from the Russian Severe Asthma Registry (RSAR)

Data from the Russian Severe Asthma Registry (RSAR)

Journal: Terapevticheskii arkhiv

Published: August 11, 2022

Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice

Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice

Journal: Terapevticheskii arkhiv

Published: April 19, 2022

Long-term follow-up study of post-COVID-19 patients

Long-term follow-up study of post-COVID-19 patients

Journal: Terapevticheskii arkhiv

Published: April 18, 2022

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.

Journal: The journal of allergy and clinical immunology. In practice

Published: July 28, 2021

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms.

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms.

Journal: International journal of chronic obstructive pulmonary disease

Published: March 06, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026